Germain, Michael J.
Paul, Subir K.
Fadda, George
Broumand, Varshasb
Nguyen, Andy
McGarvey, November H.
Gitlin, Matthew D.
Bishop, Charles W.
Csomor, Philipp
Strugnell, Stephen
Ashfaq, Akhtar
Article History
Received: 21 March 2022
Accepted: 12 October 2022
First Online: 11 November 2022
Declarations
:
: This study was conducted in compliance with the principles of the Declaration of Helsinki. The protocol was reviewed and approved by the Western Institutional Review Board (WIRB) in January 2019. A waiver of informed consent was also granted by the WIRB in February 2019 in recognition that the study was a retrospective medical record review that did not include collection or analysis of protected health information and that the requirement of collection of informed consent would make the study not feasible to conduct.
: Not applicable.
: AA, CB, and SS are employees of OPKO Health and have no other conflicts of interests to disclose. VB has received honoraria for speaking engagements on behalf of OPKO Health and has no further conflicts of interests to disclose. PC is an employee of CSL-Vifor Pharma and has no other conflicts of interest to disclose. GF, MJG, and SKP have no conflicts of interests to disclose. MDG and NHM are employed by BluePath Solutions, a company which received funding from OPKO Health to conduct the research study and have no further conflicts of interest to disclose. AN was an employee of BluePath Solutions at the time the research was conducted and has no further conflicts of interests to disclose.